Quizartinib (AC220), an FLT3 inhibitor, together with autophagy inhibitors A70 or C43, reduced cell viability of FLT3/ITD-mutated (Molm-14) and FLT3-unmutated AML cell lines (HEL, OCI-AML3). Here, FLT3 is linked to acute myeloid leukemia.